search
Back to results

Rt-fMRI Neurofeedback and AH in Schizophrenia

Primary Purpose

Audio Visual Hallucinations, Neurofeedback, Schizophrenia

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
rt-fMRI neurofeedback
Sponsored by
Harvard Medical School (HMS and HSDM)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Audio Visual Hallucinations focused on measuring rt-fMRI, MRI, schizophrenia, auditory hallucinations, neurofeedback

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • a diagnosis of schizophrenia or schizoaffective disorder based on SCID interview (DSM-5) and
  • the presence of auditory hallucinations (PANSS, item 3, score ≥4) with frequency of AH being at least once daily;
  • age between 18-55 years;
  • estimated IQ of above 80 as measured by WASI;
  • English as the primary language;
  • right-handed as determined by the Edinburgh Handedness Inventory (scoring + 60; Oldfield, 1971);
  • an ability and desire to participate in the testing program as explained by an experimenter and confirmed with a written consent form.

Exclusion Criteria:

  • history of ECT for the last 5 years;
  • history of neurological illness or a traumatic head injury, defined as loss of consciousness for more than 5 minutes and/or structural sequelae following head trauma;
  • history of severe or moderate alcohol (AUD) or substance use disorder (SUD) in the past five years, or mild AUD or SUD within the last year, according to DSM-5;
  • the use, in the preceding year of steroids or barbiturates, which can affect cognitive function;
  • hearing, vision or upper body impairment
  • alcohol use in the last 24 hours;

Sites / Locations

  • Veterans Administration Health Care System

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

rt-fMRI neurofeedback aimed at STG

sham rt-fMRI

Arm Description

One session of rt-fMRI neurofeedback from the patient's STG.

One session of rt-fMRI neurofeedback from the patient's motor cortex.

Outcomes

Primary Outcome Measures

rt-fMRI neurofeedback from STG
changes in BOLD activation in STG

Secondary Outcome Measures

rt-fMRI neurofeedback from mPFC
changes in BOLD activation in mPFC

Full Information

First Posted
March 29, 2018
Last Updated
November 28, 2022
Sponsor
Harvard Medical School (HMS and HSDM)
search

1. Study Identification

Unique Protocol Identification Number
NCT03504579
Brief Title
Rt-fMRI Neurofeedback and AH in Schizophrenia
Official Title
Real-time fMRI Feedback as a Tool to Mitigate Auditory Hallucinations in Schizophrenia
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Completed
Study Start Date
March 1, 2018 (Actual)
Primary Completion Date
March 30, 2022 (Actual)
Study Completion Date
June 30, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Harvard Medical School (HMS and HSDM)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Auditory hallucinations in schizophrenia are one of the major symptoms of this disease and a major source of psychological discomfort. They are often difficult or impossible to treat with existing methods. This study will test the use of real-time fMRI neurofeedback to mitigate auditory verbal hallucinations in patients whose hallucinations are resistant to medication. Half of the patients will receive real time fMRI neurofeedback from a brain region involved in auditory hallucinations and half will receive it from motor cortex.
Detailed Description
Auditory verbal hallucinations (AH) have long been a hallmark of schizophrenia (SZ) and are one of its major diagnostic features. They are difficult to manage with existing treatment options. Here, neurofeedback will be used to regulate the superior temporal gyrus (STG) activation which will not only lead to activation changes in the STG, but also to changes in the default mode network (DMN). The investigators will study SZ patients with medication resistant AH in the rt-fMRI intervention arm and in the sham-rt-fMRI arm. In both arms, the task and the rt-fMRI session structure will be identical. The SZ-intervention group will receive feedback from the STG while SZ-sham group will receive feedback from the motor cortex. In addition, 2 functional fMRI tasks will examine the effect of rt-fMRI neurofeedback and of sham-rt-fMRI on brain response. The investigators will randomly assign 48 SZ patients to either SZ-intervention (n=24) or SZ-sham-rtfMRI (n=24). The STG targeted neurofeedback is predicted to bring changes in brain regions involved in AH (STG and DMN) in SZ-intervention group only. The R61 GO criterion will be BOLD signal reduction in the STG, and resting state connectivity reduction between MPFC-PCC, post rt-fMRI-feedback in SZ-intervention group.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Audio Visual Hallucinations, Neurofeedback, Schizophrenia, Superior Temporal Gyrus
Keywords
rt-fMRI, MRI, schizophrenia, auditory hallucinations, neurofeedback

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
In the R61 phase of the study,changes in a target brain region(s) will be demonstrated after the rt-fMRI based neurofeedback session.
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
25 (Actual)

8. Arms, Groups, and Interventions

Arm Title
rt-fMRI neurofeedback aimed at STG
Arm Type
Experimental
Arm Description
One session of rt-fMRI neurofeedback from the patient's STG.
Arm Title
sham rt-fMRI
Arm Type
Sham Comparator
Arm Description
One session of rt-fMRI neurofeedback from the patient's motor cortex.
Intervention Type
Other
Intervention Name(s)
rt-fMRI neurofeedback
Intervention Description
use of real time fMRI neurofeedback to achieve targeted brain changes
Primary Outcome Measure Information:
Title
rt-fMRI neurofeedback from STG
Description
changes in BOLD activation in STG
Time Frame
1-2 weeks, post rt-fMRI session
Secondary Outcome Measure Information:
Title
rt-fMRI neurofeedback from mPFC
Description
changes in BOLD activation in mPFC
Time Frame
1-2 weeks, post rt-fMRI session

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: a diagnosis of schizophrenia or schizoaffective disorder based on SCID interview (DSM-5) and the presence of auditory hallucinations (PANSS, item 3, score ≥4) with frequency of AH being at least once daily; age between 18-55 years; estimated IQ of above 80 as measured by WASI; English as the primary language; right-handed as determined by the Edinburgh Handedness Inventory (scoring + 60; Oldfield, 1971); an ability and desire to participate in the testing program as explained by an experimenter and confirmed with a written consent form. Exclusion Criteria: history of ECT for the last 5 years; history of neurological illness or a traumatic head injury, defined as loss of consciousness for more than 5 minutes and/or structural sequelae following head trauma; history of severe or moderate alcohol (AUD) or substance use disorder (SUD) in the past five years, or mild AUD or SUD within the last year, according to DSM-5; the use, in the preceding year of steroids or barbiturates, which can affect cognitive function; hearing, vision or upper body impairment alcohol use in the last 24 hours;
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
margaret niznikiewicz, ph.d
Organizational Affiliation
VA Boston Healthcare System
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
susan whitfield-Gabrieli, Ph.D.
Organizational Affiliation
Massachusetts Institute of Technology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Veterans Administration Health Care System
City
Brockton
State/Province
Massachusetts
ZIP/Postal Code
02301
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Rt-fMRI Neurofeedback and AH in Schizophrenia

We'll reach out to this number within 24 hrs